Search research articles
Contact Us
Filters
Showing results (621-630 of 1,645) with videos related to
Page
of 165
Sort By:
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 30, 2012
Effects of exercise training on airway closure in asthmatics
Nicola Scichilone, Giuseppe Morici, Daniele Zangla, et al.
Medical Hypotheses
|
March 23, 2005
Potentiation of immunological tolerance induction in adult mice by co-administration of pooled normal IgG and oral tolerogens: a potential therapeutic approach for autoimmune diseases
José Mengel, Patrícia Fávaro, André Meyer, et al.
Sensors (Basel, Switzerland)
|
June 27, 2024
Development of a Simple Setup to Measure Shielding Effectiveness at Microwave Frequencies
Emanuele Cardillo, Fabrizio Lorenzo Carcione, Luigi Ferro, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society
|
July 2, 2024
Post-surgical spontaneous paroxysmal hypothermia: a case series
Cristina Cuccagna, Francesca Schinzari, Chiara Piccininni, et al.
Translational Lung Cancer Research
|
June 24, 2021
Managing of screening-detected sub-solid nodules-a European perspective
Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, et al.
International Journal of Retina and Vitreous
|
June 2, 2022
Pascal short-pulse plus subthreshold endpoint management laser therapy for diabetic macular edema: the "sandwich technique"
J A Cardillo, M W Rodrigues, R C Oliveira, et al.
Journal of Hypertension
|
August 1, 1994
Platelet alpha 2-adrenoceptors and diurnal changes of platelet aggregability in hypertensive patients
N Mores, M Martire, G Pistritto, et al.
Molecular Cancer Therapeutics
|
May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Chien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget
|
June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Oncotarget
|
March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Page
of 165
Search research articles
Search
Showing results (621-630 of 1,645) with videos related to
Sort By:
Page
of 165
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
June 30, 2012
Effects of exercise training on airway closure in asthmatics
Nicola Scichilone, Giuseppe Morici, Daniele Zangla, et al.
Medical Hypotheses
|
March 23, 2005
Potentiation of immunological tolerance induction in adult mice by co-administration of pooled normal IgG and oral tolerogens: a potential therapeutic approach for autoimmune diseases
José Mengel, Patrícia Fávaro, André Meyer, et al.
Sensors (Basel, Switzerland)
|
June 27, 2024
Development of a Simple Setup to Measure Shielding Effectiveness at Microwave Frequencies
Emanuele Cardillo, Fabrizio Lorenzo Carcione, Luigi Ferro, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society
|
July 2, 2024
Post-surgical spontaneous paroxysmal hypothermia: a case series
Cristina Cuccagna, Francesca Schinzari, Chiara Piccininni, et al.
Translational Lung Cancer Research
|
June 24, 2021
Managing of screening-detected sub-solid nodules-a European perspective
Sara Ricciardi, Richard Booton, Renè Horsleben Petersen, et al.
International Journal of Retina and Vitreous
|
June 2, 2022
Pascal short-pulse plus subthreshold endpoint management laser therapy for diabetic macular edema: the "sandwich technique"
J A Cardillo, M W Rodrigues, R C Oliveira, et al.
Journal of Hypertension
|
August 1, 1994
Platelet alpha 2-adrenoceptors and diurnal changes of platelet aggregability in hypertensive patients
N Mores, M Martire, G Pistritto, et al.
Molecular Cancer Therapeutics
|
May 22, 2016
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
Chien-Hsing Chang, Yang Wang, Maria Zalath, et al.
Oncotarget
|
June 24, 2015
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Oncotarget
|
March 25, 2020
Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
David M Goldenberg, Thomas M Cardillo, Serengulam V Govindan, et al.
Page
of 165